1 57) after excluding trials using polymyxin B hemoperfusion.

2 tients both before and at various times post-hemoperfusion.

3 eptic shock and terms related to polymyxin B hemoperfusion.

4                                              Hemoperfusion and on-line removal of superantigens merit

5 inly influenced by studies using polymyxin B hemoperfusion from Japan.

6 nt time, endotoxin removal through cartridge hemoperfusion is one of the better alternatives to comba

7 dies investigating the effect of polymyxin B hemoperfusion on mortality were considered eligible.

8 81 (95% CI, 0.70-0.95), favoring polymyxin B hemoperfusion (p = 0.007).

9      Blood purification techniques including hemoperfusion, plasma exchange, and hemofiltration with

10 However, these results were driven mainly by hemoperfusion (risk ratio, 0.63 [95% CI, 0.50-0.80]; p<0

11 rough a alphaGal6 immunoaffinity column with hemoperfusion through a pig liver for changes in blood p

12                                Hemodialysis, hemoperfusion, thymidine, and carboxypeptidase have been

13  reported a survival benefit for polymyxin B hemoperfusion treatment in patients with severe sepsis a

14  present study demonstrated that polymyxin B hemoperfusion treatment may reduce mortality in patients

15 lysis to determine the effect of polymyxin B hemoperfusion treatment on mortality in patients with se

16 reported no survival benefit for polymyxin B hemoperfusion treatment.

17 asmapheresis, thalidomide, cyclophosphamide, hemoperfusion, tumor necrosis factor inhibitors, and gra

18 blood purification therapy comprising direct hemoperfusion using a polymyxin B-immobilized fiber colu

19 on, plasma exchange, and hemofiltration with hemoperfusion were associated with lower mortality in pa